MD Anderson Ovarian SPORE publications – 2008
1.
Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K,
Workman P. Opportunities and challenges in ovarian cancer research, a perspective from the
11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol 108(3):652-7,
2008. PMID: 18096210.
2.
Astanehe A, Arenillas D, Wasserman WW, Leung PC, Dunn SE, Davies BR, Mills GB, Auersperg N.
Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium
and in ovarian cancer. J Cell Sci 121(Pt 5):664-74, 2008. PMID: 18270270.
3.
Baggerly KA, Coombes KR, Neeley ES. Run batch effects potentially compromise the usefulness
of genomic signatures for ovarian cancer. J Clin Oncol 26(7):1186-7; author reply 7-8, 2008. PMID:
18309960.
4.
Bartholomeusz C, Rosen D, Wei C, Kazansky A, Yamasaki F, Takahashi T, Itamochi H, Kondo S, Liu J,
Ueno NT. PEA-15 induces autophagy in human ovarian cancer cells and is associated with
prolonged overall survival. Cancer Res 68(22):9302-10, 2008. PMID: 19010903; PMCID:
PMC2676677.
5.
Bennett P, Wilkinson C, Turner J, Brain K, Edwards RT, Griffith G, France B, Gray J. Psychological
factors associated with emotional responses to receiving genetic risk information. J Genet
Couns 17(3):234-41, 2008. PMID: 18259848.
6.
Boruban MC, Jaishuen A, Sirisabya N, Li Y, Zheng HG, Deavers MT, Kavanagh JJ. Ovarian
endometriosis associated with carcinoma and sarcoma: case report. Eur J Gynaecol Oncol
29(4):393-6, 2008. PMID: 18714578.
7.
Brown LA, Kalloger SE, Miller MA, Shih Ie M, McKinney SE, Santos JL, Swenerton K, Spellman PT,
Gray J, Gilks CB, Huntsman DG. Amplification of 11q13 in ovarian carcinoma. Genes
Chromosomes Cancer 47(6):481-9, 2008. PMID: 18314909.
8.
Coleman RL, Kohn EC. Rationale for combination use of targeted agents in ovarian cancer: do
we have one? Cancer 113(4):665-7, 2008. PMID: 18623195.
9.
Das PM, Bast RC Jr. Early detection of ovarian cancer. Biomark Med 2(3):291-303, 2008. PMID:
20477415; PMCID: PMC2930760.
10.
Demizu Y, Sasaki R, Trachootham D, Pelicano H, Colacino JA, Liu J, Huang P. Alterations of cellular
redox state during NNK-induced malignant transformation and resistance to radiation. Antioxid
Redox Signal 10(5):951-61, 2008. PMID: 18257743; PMCID: PMC2717788.
11.
Devine KM, Smicun Y, Hope JM, Fishman DA. S1P induced changes in epithelial ovarian cancer
proteolysis, invasion, and attachment are mediated by Gi and Rac. Gynecol Oncol 110(2):237-45,
2008. PMID: 18513786; PMCID: PMC3984540.
12.
Dimple C, Nair SS, Rajhans R, Pitcheswara PR, Liu J, Balasenthil S, Le XF, Burow ME, Auersperg N,
Tekmal RR, Broaddus RR, Vadlamudi RK. Role of PELP1/MNAR signaling in ovarian
tumorigenesis. Cancer Res 68(12):4902-9, 2008. PMID: 18559538.
13.
Ding Q, Huo L, Yang JY, Xia W, Wei Y, Liao Y, Chang CJ, Yang Y, Lai CC, Lee DF, Yen CJ, Chen YJ,
Hsu JM, Kuo HP, Lin CY, Tsai FJ, Li LY, Tsai CH, Hung MC. Down-regulation of myeloid cell
leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in
breast cancer. Cancer Res 68(15):6109-17, 2008. PMID: 18676833; PMCID: PMC2676572.
14.
Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC Jr. Imprinted tumor
suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian
cancers by loss of heterozygosity and promoter methylation. Cancer 112(7):1489-502, 2008.
PMID: 18286529.
15.
Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng
Q, Durden DL. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126,
with antitumor and antiangiogenic activity. Cancer Res 68(1):206-15, 2008. PMID: 18172313.
16.
Guo W, Wu S, Liu J, Fang B. Identification of a small molecule with synthetic lethality for K-ras
and protein kinase C iota. Cancer Res 68(18):7403-8, 2008. PMID: 18794128; PMCID:
PMC2678915.
17.
Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth
WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK. HLA class I
antigen processing machinery component expression and intratumoral T-Cell infiltrate as
independent prognostic markers in ovarian carcinoma. Clin Cancer Res 14(11):3372-9, 2008.
PMID: 18519766; PMCID: PMC3426216.
18.
Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, Almeida J, Coombes KR, Liu J, Lu Y,
Gray JW, Mills GB. Ovarian cancer: linking genomics to new target discovery and molecular
markers--the way ahead. Adv Exp Med Biol 617:23-40, 2008. PMID: 18497028; PMCID:
PMC2844243.
19.
Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation
of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary
peritoneal cancer. Gynecol Oncol 111(3):467-73, 2008. PMID: 18834619.
20.
Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, VivasMejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological
significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 68(14):5849-58, 2008.
PMID: 18632639; PMCID: PMC2547344.
21.
Jaishuen A, Berrios-Rivera JP, Sirisabya N, Zheng HG, Li Y, Kavanagh JJ. Erosive osteoarthritis
during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous
carcinoma of the ovary. Int J Gynecol Cancer 18(2):379-83, 2008. PMID: 17624988.
22.
Jandial DD, Soliman PT, Slomovitz BM, Schmeler KM, Levenback C, Coleman RL, Ramirez PT.
Laparoscopic colostomy in gynecologic cancer. J Minim Invasive Gynecol 15(6):723-8, 2008.
PMID: 18971136.
23.
Ji Y, Lu Y, Mills GB. Bayesian models based on test statistics for multiple hypothesis testing
problems. Bioinformatics 24(7):943-9, 2008. PMID: 18245123.
24.
Kavanagh JJ, Sill MW, Ramirez PT, Warshal D, Pearl ML, Morgan MA. Phase II multicenter openlabel study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer:
a Gynecologic Oncology Group Study. Int J Gynecol Cancer 18(3):460-4, 2008. PMID: 17854432.
25.
Kubba LA, McCluggage WG, Liu J, Malpica A, Euscher ED, Silva EG, Deavers MT. Thyroid
transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol 21(4):485-90, 2008.
PMID: 18246044.
26.
Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, Lu KH. Cost-effectiveness
analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer
113(2):326-35, 2008. PMID: 18506736.
27.
Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB,
Lu KH. What women with ovarian cancer think and know about genetic testing. Gynecol Oncol
111(1):132-6, 2008. PMID: 18684498; PMCID: PMC3746752.
28.
Lague MN, Paquet M, Fan HY, Kaartinen MJ, Chu S, Jamin SP, Behringer RR, Fuller PJ, Mitchell A,
Dore M, Huneault LM, Richards JS, Boerboom D. Synergistic effects of Pten loss and
WNT/CTNNB1 signaling pathway activation in ovarian granulosa cell tumor development and
progression. Carcinogenesis 29(11):2062-72, 2008. PMID: 18687666; PMCID: PMC2577137.
29.
Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maiseri H, DeGeest K, Sood AK, Lubaroff DM. Positive
psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun 22(1):65-73,
2008. PMID: 17643954; PMCID: PMC2964139.
30.
Landen CN, Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer.
J Clin Oncol 26(6):995-1005, 2008. PMID: 18195328.
31.
Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB,
Kinch MS, Tice D, Sood AK. Tumor-selective response to antibody-mediated targeting of
alphavbeta3 integrin in ovarian cancer. Neoplasia 10(11):1259-67, 2008. PMID: 18953435; PMCID:
PMC2570602.
32.
Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC Jr. Specific blockade of VEGF
and HER2 pathways results in greater growth inhibition of breast cancer xenografts that
overexpress HER2. Cell Cycle 7(23):3747-58, 2008. PMID: 19029832; PMCID: PMC2757147.
33.
Li YF, Hu W, Fu SQ, Li JD, Liu JH, Kavanagh JJ. Aromatase inhibitors in ovarian cancer: is there a
role? Int J Gynecol Cancer 18(4):600-14, 2008. PMID: 17894799.
34.
Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu
C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Jr, Wong KK, Gray MJ, Coleman RL,
Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer
growth. Clin Cancer Res 14(17):5437-46, 2008. PMID: 18765535; PMCID: PMC2766914.
35.
Liu S, Fang X, Hall H, Yu S, Smith D, Lu Z, Fang D, Liu J, Stephens LC, Woodgett JR, Mills GB.
Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras
transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A 105(13):5248-53, 2008.
PMID: 18367674; PMCID: PMC2278194.
36.
Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M,
Sood AK. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7(7):1098103, 2008. PMID: 18443431; PMCID: PMC2705979.
37.
Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR,
Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel
maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 198(4):477.e1-9;
discussion .e9-10, 2008. PMID: 18395047; PMCID: PMC2346589.
38.
Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and
surgical prophylaxis. Fam Cancer 7(1):53-8, 2008. PMID: 17636427.
39.
Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC Jr.
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian
cancer cells. J Clin Invest 118(12):3917-29, 2008. PMID: 19033662; PMCID: PMC2582930.
40.
Lutgendorf SK, Lamkin DM, DeGeest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H,
Sood AK, Lubaroff DM. Depressed and anxious mood and T-cell cytokine expressing populations
in ovarian cancer patients. Brain Behav Immun 22(6):890-900, 2008. PMID: 18276105; PMCID:
PMC2605940.
41.
Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, Langley RR, Lucci JA,
3rd, Cole SW, Lubaroff DM, Sood AK. Biobehavioral influences on matrix metalloproteinase
expression in ovarian carcinoma. Clin Cancer Res 14(21):6839-46, 2008. PMID: 18980978; PMCID:
PMC2716059.
42.
Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, Henderson PJ, Sephton
SE, Rohleder N, Lucci JA, 3rd, Cole S, Sood AK, Lubaroff DM. Interleukin-6, cortisol, and
depressive symptoms in ovarian cancer patients. J Clin Oncol 26(29):4820-7, 2008. PMID:
18779606; PMCID: PMC2653140.
43.
Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K,
Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N,
Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Skates S, Parmar M, Jacobs I.
Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. BMJ 337:a2079,
2008. PMID: 19008269; PMCID: PMC2583394.
44.
Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA,
Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok
S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in
patients with ovarian cancer. N Engl J Med 359(25):2641-50, 2008. PMID: 19092150; PMCID:
PMC2710981.
45.
Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De
Geest K, Langley RR, Villares G, Sanguino A, Lutgendorf SK, Lopez-Berestein G, Bar-Eli MM, Sood
AK. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on
ovarian cancer cell growth. J Natl Cancer Inst 100(5):359-72, 2008. PMID: 18314475; PMCID:
PMC2770251.
46.
Monahan PO, Champion VL, Zhao Q, Miller AM, Gershenson D, Williams SD, Cella D. Case-control
comparison of quality of life in long-term ovarian germ cell tumor survivors: a gynecologic
oncology group study. J Psychosoc Oncol 26(3):19-42, 2008. PMID: 19042263.
47.
Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K. Utility of
a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the
uterus. Gynecol Oncol 110(2):196-201, 2008. PMID: 18495222; PMCID: PMC3594093.
48.
Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro
P, Granai CO, Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of
ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 108(2):402-8, 2008. PMID:
18061248.
49.
Morgan RJ, Jr, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, Fowler J, Gaffney DK,
Gershenson D, Greer BE, Grigsby PW, Havrilesky LJ, Johnston C, Lancaster JM, Lele S, Matulonis U,
O'Malley D, Ozols RF, Remmenga SW, Sabbatini P, Schink J, Teng N. Ovarian cancer. Clinical
practice guidelines in oncology. J Natl Compr Canc Netw 6(8):766-94, 2008. PMID: 18926089.
50.
Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev
Cancer 8(11):835-50, 2008. PMID: 18948996.
51.
Muller M, Obeyesekere M, Mills GB, Ram PT. Network topology determines dynamics of the
mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by
FGFR and MC1R. FASEB J 22(5):1393-403, 2008. PMID: 18171696.
52.
Mulligan P, Westbrook TF, Ottinger M, Pavlova N, Chang B, Macia E, Shi YJ, Barretina J, Liu J, Howley
PM, Elledge SJ, Shi Y. CDYL bridges REST and histone methyltransferases for gene repression
and suppression of cellular transformation. Mol Cell 32(5):718-26, 2008. PMID: 19061646.
53.
Murph MM, Nguyen GH, Radhakrishna H, Mills GB. Sharpening the edges of understanding the
structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation.
Biochim Biophys Acta 1781(9):547-57, 2008. PMID: 18501205; PMCID: PMC2565514.
54.
Murph MM, Smith DL, Hennessy B, Lu Y, Joy C, Coombes KR, Mills GB. Individualized molecular
medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for
specific patients. Adv Exp Med Biol 622:183-95, 2008. PMID: 18546628.
55.
Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, Schmandt R, Smith-McCune K, Fishman D,
Gray JW, Mills GB. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian
cancers: a role in ovarian pathogenesis. Mol Oncol 2(2):164-81, 2008. PMID: 19383336; PMCID:
PMC2598416.
56.
Nick AM, Sood AK. The ROC 'n' role of the multiplex assay for early detection of ovarian cancer.
Nat Clin Pract Oncol 5(10):568-9, 2008. PMID: 18695710.
57.
Oyesanya RA, Lee ZP, Wu J, Chen J, Song Y, Mukherjee A, Dent P, Kordula T, Zhou H, Fang X.
Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced
cyclooxygenase-2 expression in ovarian cancer cells. Faseb j 22(8):2639-51, 2008. PMID:
18362203; PMCID: PMC2493458.
58.
Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong
KK. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer.
Neoplasia 10(9):964-72, 2008. PMID: 18714397; PMCID: PMC2517641.
59.
Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA,
Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG.
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular
abnormalities. BMC Cancer 8:17, 2008. PMID: 18208621; PMCID: PMC2245962.
60.
Ramirez PT, Landen CN, Jr, Coleman RL, Milam MR, Levenback C, Johnston TA, Gershenson DM.
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients
with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol 108(1):68-71, 2008. PMID:
17905421.
61.
Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, Deavers M, Levenback
C, Coleman RL, Gershenson DM. Efficacy of letrozole in the treatment of recurrent platinum- and
taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol 110(1):56-9, 2008.
PMID: 18457865.
62.
Ramus SJ, Elmasry K, Luo Z, Gammerman A, Lu K, Ayhan A, Singh N, McCluggage WG, Jacobs IJ,
Whittaker JC, Gayther SA. Predicting clinical outcome in patients diagnosed with synchronous
ovarian and endometrial cancer. Clin Cancer Res 14(18):5840-8, 2008. PMID: 18794095.
63.
Raphael BJ, Volik S, Yu P, Wu C, Huang G, Linardopoulou EV, Trask BJ, Waldman F, Costello J,
Pienta KJ, Mills GB, Bajsarowicz K, Kobayashi Y, Sridharan S, Paris PL, Tao Q, Aerni SJ, Brown RP,
Bashir A, Gray JW, Cheng JF, de Jong P, Nefedov M, Ried T, Padilla-Nash HM, Collins CC. A
sequence-based survey of the complex structural organization of tumor genomes. Genome Biol
9(3):R59, 2008. PMID: 18364049; PMCID: PMC2397511.
64.
Ren W, Korchin B, Lahat G, Wei C, Bolshakov S, Nguyen T, Merritt W, Dicker A, Lazar A, Sood A,
Pollock RE, Lev D. Combined vascular endothelial growth factor receptor/epidermal growth
factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft
tissue sarcoma. Clin Cancer Res 14(17):5466-75, 2008. PMID: 18765538.
65.
Sanguino A, Lopez-Berestein G, Sood AK. Strategies for in vivo siRNA delivery in cancer. Mini Rev
Med Chem 8(3):248-55, 2008. PMID: 18336345.
66.
Schmeler KM, Gershenson DM. Low-grade serous ovarian cancer: a unique disease. Curr Oncol
Rep 10(6):519-23, 2008. PMID: 18928667.
67.
Schmeler KM, Lu KH. Gynecologic cancers associated with Lynch syndrome/HNPCC. Clin Transl
Oncol 10(6):313-7, 2008. PMID: 18558577.
68.
Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson
DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Gynecol Oncol 108(3):510-4, 2008. PMID: 18155273.
69.
Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY. Cancer stem
cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer
Res 68(9):3243-50, 2008. PMID: 18451150; PMCID: PMC2929908.
70.
Sirisabya N, Li Y, Jaishuen A, Zheng HG, Gershenson DM, Kavanagh JJ. Tamoxifen is safe and
effective in gynecological cancer patients with renal dysfunction. Int J Gynecol Cancer 18(4):64851, 2008. PMID: 17892459.
71.
Smith JA, Gaikwad A, Yu J, Wolf JK, Brown J, Ramondetta LM, Stewart CF. In vitro evaluation of the
effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a
panel of human ovarian cancer cell lines. Cancer Chemother Pharmacol 62(1):51-8, 2008. PMID:
17849119.
72.
Sood AK, Birrer MJ. Highlights from the 2008 Annual Meeting of the American Association for
Cancer Research. Gynecol Oncol 110(1):5-6, 2008. PMID: 18595162.
73.
Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer
therapy. Nat Clin Pract Oncol 5(4):194-204, 2008. PMID: 18268546.
74.
Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK,
Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic
analysis. Adv Exp Med Biol 622:23-33, 2008. PMID: 18546616.
75.
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y,
Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero
V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of
PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084-91, 2008. PMID:
18676830; PMCID: PMC2680495.
76.
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, Babaian R, Bast RC Jr, Dowell B,
Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH,
Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih Ie M, Sibley P, Soletormos G, Stephan C,
Sokoll L, Hoffman BR, Diamandis EP. National Academy of Clinical Biochemistry laboratory
medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast,
and ovarian cancers. Clin Chem 54(12):e11-79, 2008. PMID: 19042984.
77.
Sun Y, Wong N, Guan Y, Salamanca CM, Cheng JC, Lee JM, Gray JW, Auersperg N. The eukaryotic
translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic
effects of ZNF217 in precursor cells of human ovarian carcinomas. Int J Cancer 123(8):1761-9,
2008. PMID: 18661515; PMCID: PMC2606039.
78.
Tao X, Kavanagh JJ. Chemotherapy for gynecological malignancies in organ transplantation
patients: report of two cases. Int J Gynecol Cancer 18(6):1376-80, 2008. PMID: 18462370.
79.
Thaker PH, Sood AK. Neuroendocrine influences on cancer biology. Semin Cancer Biol 18(3):16470, 2008. PMID: 18201896; PMCID: PMC2424028.
80.
Tung CS, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl)
4:27-40, 2008. PMID: 19072449.
81.
Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia PE, LopezBerestein G, Sood AK, Bar-Eli M. Targeting melanoma growth and metastasis with systemic
delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer
Res 68(21):9078-86, 2008. PMID: 18974154; PMCID: PMC2597081.
82.
Wang D, Zhao Z, Caperell-Grant A, Yang G, Mok SC, Liu J, Bigsby RM, Xu Y. S1P differentially
regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol
Cancer Ther 7(7):1993-2002, 2008. PMID: 18645009; PMCID: PMC2649755.
83.
Wang X, Urvalek AM, Liu J, Zhao J. Activation of KLF8 transcription by focal adhesion kinase in
human ovarian epithelial and cancer cells. J Biol Chem 283(20):13934-42, 2008. PMID: 18353772.
84.
Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC Jr,
Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in
the mouse. Differentiation 76(10):1081-92, 2008. PMID: 18637025; PMCID: PMC2593124.
85.
Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast
RC Jr, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of
poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47(9):701-6, 2008. PMID:
18176935; PMCID: PMC2580832.
86.
Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC,
Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin
AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by
inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10(2):138-48, 2008. PMID:
18204439; PMCID: PMC2376808.
87.
Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L,
Johnstone CN, Chen XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, Butzow R, Croce CM,
Coukos G, Zhang L. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic
target in human epithelial ovarian cancer. Cancer Res 68(24):10307-14, 2008. PMID: 19074899;
PMCID: PMC2762326.
88.
Yeung BH, Kwan BW, He QY, Lee AS, Liu J, Wong AS. Glucose-regulated protein 78 as a novel
effector of BRCA1 for inhibiting stress-induced apoptosis. Oncogene 27(53):6782-9, 2008. PMID:
18776923.
89.
Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. Lysophosphatidic acid
receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer
Inst 100(22):1630-42, 2008. PMID: 19001604; PMCID: PMC2720766.
90.
Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn M, Godwin
AK, Nuciforo PG, Cavallaro U. The differential role of L1 in ovarian carcinoma and normal ovarian
surface epithelium. Cancer Res 68(4):1110-8, 2008. PMID: 18281486.
91.
Zhai QJ, Rosen DG, Lu K, Liu J. Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is
histotype-specific. Int J Clin Exp Pathol 1(6):502-9, 2008. PMID: 18787632; PMCID: PMC2480583.
92.
Zheng H, Hu W, Yu D, Shen DY, Fu S, Kavanagh JJ, Wei IC, Yang DJ. Diammine dicarboxylic acid
platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of
apoptosis and S-phase cell arrest. Pharm Res 25(10):2272-82, 2008. PMID: 18509599.